Searchable abstracts of presentations at key conferences in endocrinology

ea0063p730 | Pituitary and Neuroendocrinology 2 | ECE2019

Trial-in-progress: A multicenter, dose-titration, open-label phase 2b study of nevanimibe hydrochloride, A novel ACAT1 inhibitor, for the treatment of classic congenital adrenal hyperplasia

Lin Vivian , Marian Ijzerman M , Plaunt Marianne , Mohideen Pharis

More than 90% of classic congenital adrenal hyperplasia (CAH) patients have defects in the cytochrome P450 enzyme steroid 21-hydroxylase, resulting in the inability to produce cortisol as well as the overproduction of androgens and androgen precursors such as 17-hydroxyprogesterone (17-OHP). Management of classic CAH can be challenging since patients are often unable to adequately balance the supraphysiologic doses of exogenous glucocorticoids required to suppress excess andro...